Two Sigma Investments LP Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Two Sigma Investments LP purchased a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 112,458 shares of the company's stock, valued at approximately $1,498,000. Two Sigma Investments LP owned approximately 0.43% of Eton Pharmaceuticals at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of ETON. Anchor Capital Advisors LLC bought a new position in shares of Eton Pharmaceuticals during the fourth quarter valued at $805,000. Raymond James Financial Inc. purchased a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at $147,000. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Eton Pharmaceuticals by 230.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock valued at $2,862,000 after buying an additional 149,864 shares during the last quarter. Thompson Siegel & Walmsley LLC boosted its position in shares of Eton Pharmaceuticals by 11.3% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 128,039 shares of the company's stock valued at $1,705,000 after buying an additional 13,009 shares during the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at $226,000. 27.86% of the stock is currently owned by institutional investors.

Eton Pharmaceuticals Stock Down 2.4%

NASDAQ:ETON traded down $0.41 on Friday, hitting $16.84. The stock had a trading volume of 404,191 shares, compared to its average volume of 214,015. The stock has a market cap of $451.62 million, a price-to-earnings ratio of -76.55 and a beta of 1.22. The business's 50-day simple moving average is $16.24 and its two-hundred day simple moving average is $14.89. Eton Pharmaceuticals, Inc. has a 52-week low of $3.18 and a 52-week high of $21.48.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02). The firm had revenue of $17.28 million during the quarter, compared to analysts' expectations of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, equities research analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. B. Riley reaffirmed a "buy" rating and set a $26.00 price objective (up from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective (up from $33.00) on shares of Eton Pharmaceuticals in a research report on Thursday, May 29th. Finally, Craig Hallum raised their target price on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.